(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 6.84% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Bio Techne's revenue in 2024 is $1,144,999,000.On average, 5 Wall Street analysts forecast TECH's revenue for 2024 to be $180,683,825,132, with the lowest TECH revenue forecast at $179,890,164,314, and the highest TECH revenue forecast at $181,572,115,344. On average, 5 Wall Street analysts forecast TECH's revenue for 2025 to be $197,221,333,544, with the lowest TECH revenue forecast at $193,738,751,763, and the highest TECH revenue forecast at $200,081,279,061.
In 2026, TECH is forecast to generate $221,453,374,937 in revenue, with the lowest revenue forecast at $218,676,269,438 and the highest revenue forecast at $222,897,809,330.